J&J arthritis drug sirukumab raises safety concerns: FDA staff

J&J arthritis drug sirukumab raises safety concerns: FDA staffThere were more deaths in patients taking Johnson & Johnson’s experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, staff reviewers for the U.S. Food and Drug Administration said in a report published Monday. The FDA is not obliged to follow the advice of its advisers but typically does so. The most common causes of death were major heart problems, infection and malignancies.



Yahoo News – Latest News & Headlines